Absci is trading at $9.65, down 5.02%, with the cause of the decline unclear.
- No clear company-specific announcement explaining Absci’s October 12 decline was found. Its latest identified update concerned preliminary details for the ABS-201 Phase 2 trial, not a confirmed catalyst for this move.
- The broader market was nearly flat, while some biotech peers gained; neither establishes a clear explanation for Absci’s drop.
- Available evidence does not support attributing the decline to a specific event.